Cancer-drug setback sends Merck shares down again


A setback for Merck & Co's key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years. The logo of Merck is pictured in this illustration photograph in Cardiff, California April 26, 2016.



from Biotech News